When was Parabilis Medicines founded?

Parabilis Medicines was founded in 2016 and raised its 1st funding round 6 years after it was founded.

Where is Parabilis Medicines located?

Parabilis Medicines is headquartered in Cambridge, United States.

Who is the current CEO of Parabilis Medicines?

Mathai Mammen of Parabilis Medicines.

How many employees does Parabilis Medicines have?

As of Sep 30, 2026, the latest employee count at Parabilis Medicines is 216.

Is Parabilis Medicines a funded company?

Parabilis Medicines is a funded company, having raised a total of $628M across 3 funding rounds to date. The company's 1st funding round was a $***** Series D round, raised on Nov 17, 2022.

When was the latest funding round of Parabilis Medicines?

Parabilis Medicines' latest funding was a $***** Series F round on Jan 08, 2026, with participation from 20 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $6.7B in funding in 2026 to date.

Where does Parabilis Medicines rank among its competitors?

Parabilis Medicines ranks 1st amongst 24 active competitors, of which 9 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Parabilis Medicines, which secured $305M in Jan, 2026.

Who are the top competitors of Parabilis Medicines?

Parabilis Medicines' top competitors include Check-Cap, Sunbird Bio and Akamis Bio. Among them, Parabilis Medicines secured the most recent funding round in January, 2026.

Parabilis Medicines - 2026 Company Profile, Team, Funding & Competitors

Parabilis Medicines is a public company based in Cambridge (United States), founded in 2016. It operates as a Developer of peptide therapeutics for the treatment of severe diseases. Parabilis Medicines has raised $628M in funding from investors like Fidelity Investments, Google Ventures and T. Rowe Price. The company has 24 active competitors, including 9 funded and 3 that have exited. Its top competitors include companies like Check-Cap, Sunbird Bio and Akamis Bio.

Company Details

Developer of peptide therapeutics for the treatment of severe diseases. It offers a proprietary AI- and physics-based computational methods as discovery platform . It offers FOG-001 an inhibitor of β-catenin:TCF for colorectal cancers.

Website: parabilismed.com
Email ID: *****@parabilismed.com
Phone Number: +1 **********

Key Metrics

Founded Year

2016

Location

Cambridge, United States

Stage

Public

Total Funding

$628M in 3 rounds

Latest Funding Round

Series F, Jan 08, 2026, $*****

Investors

Fidelity Investments & 28 more

Ranked

1^st among 24 active competitors

Employee Count

216 as on Sep 30, 2026

Similar Companies

Sunbird Bio & 18 more

Exit Details

Public

View Parabilis Medicines' full profile

Parabilis Medicines is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Fog Pharmaceuticals, Inc CIN: 47-4505725 , Belgium, Active	Jul 09, 2015	-	97 (As on Dec 31, 2021)	-

Parabilis Medicines got listed on Jun 10, 2026.

Click here to take a look at Parabilis Medicines's IPO in detail

Parabilis Medicines has raised a total funding of $628M over 3 rounds. Its first funding round was on Nov 17, 2022. Its latest funding round was a Series F round on Jan 08, 2026 for $*****. 20 investors participated in its latest round. Parabilis Medicines has 28 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Parabilis Medicines:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 08, 2026	7524078	Series F	6837059	9828730	5890232	9386998
Mar 01, 2024	3741369	Series E	8569811	4424741	6978718	Rock Springs Capital & 13 more
Nov 17, 2022	4057276	Series D	3018748	3476651	Arch Venture Partners & 12 more	6098658

Access funding benchmarks and valuations. Sign up today!

View details of Parabilis Medicines's funding rounds and investors

Parabilis Medicines' employee count trend

Parabilis Medicines has 216 employees as of Sep 26. Here is Parabilis Medicines's employee count trend over the years:

Employee count trend for Parabilis Medicines

Uncover Parabilis Medicines' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Parabilis Medicines include Check-Cap, Sunbird Bio and Akamis Bio. Here is the list of Top 10 competitors of Parabilis Medicines, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Parabilis Medicines 2016, Cambridge (United States), Public	Developer of peptide therapeutics for the treatment of severe diseases	$628M	T. Rowe Price, Foresite Capital & 27 others	61/100
2nd	Check-Cap 2005, Haifa (Israel), Public	Developer of imaging capsules for colorectal cancer screening	$9.88M	Pontifax, Docor & 11 others	60/100
3rd	Sunbird Bio 2020, Singapore, Series B	Developer of blood-based diagnostic tests for neurological disorders	$14M	Lilly, EDBI & 9 others	58/100
4th	Akamis Bio 2010, Cambridge (United States), Series D	Developer of therapeutics for the treatment of colorectal cancer	$179M	Imperial Innovations, Mercia & 30 others	54/100
5th	Lutris Pharma 2016, Tel Aviv (Israel), Series B	Provider of anti-cancer therapy	$30M	Pontifax, Columbus Venture Partners & 3 others	47/100
6th	New Element Medicine 2012, Zhenjiang (China), Series D	Developer of drugs for various cancer	$152M	Kaitai Capital Management, ShenZhen GTJA Investment Group ... & 11 others	41/100
7th	Isofol Medical 2008, Gothenburg (Sweden), Public	Developer of small molecules for colorectal cancer	-	Sahlgrenska Science Park	41/100
8th	ResistanceBio 2016, Menlo Park (United States), Series A	Developer of therapeutics for treatment-resistant cancer	$12.9M	NFX, Y Combinator & 17 others	34/100
9th	Jiangsu Sinorda Biomedicine 2010, Suzhou (China), Deadpooled	Developing personalised anticancer vaccines & diagnostics	-	Guiyang Venture Capital, Button Capital	32/100
10th	Origo Biopharma 2017, Ourense (Spain), Acqui-Hired	Manufacturer of immunotherapeutic products for research purpose	$2.6M	Asabys Partners, Xesgalicia	32/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Parabilis Medicines's competitors? Click here to see the top ones

Parabilis Medicines has made no investments or acquisitions yet.

Here is the latest report on Parabilis Medicines's sector:

Free

Oncology - Sector Report

Edition: September, 2026 (75 Pages)

View all reports related to Parabilis Medicines

Media has covered Parabilis Medicines for a total of 18 events in the last 1 year, 4 of them have been about company updates and 2 about partnerships.